April 30, 2014 | The United States Food and Drug Administration (FDA) has approved the start of multi-center Phase II clinical trials in the United States to treat amyotrophic lateral sclerosis (ALS). The treatment will use adult stem cell technology, first introduced by the Hadassah Medical Center’s Professor Dimitrios Karussis, Senior Neurologist and head of Hadassah’s Multiple Sclerosis Center.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments